Bulletin of Experimental Biology and Medicine

, Volume 147, Issue 1, pp 26–30

Effects of Prolylendopeptidase Inhibitor Benzyloxycarbonyl-Methionyl-2(S)-Cyanopyrrolidine on Experimental Depressive Syndrome Development in Rats

  • N. N. Khlebnikova
  • N. A. Krupina
  • N. G. Bogdanova
  • N. N. Zolotov
  • G. N. Kryzhanovskii
General Pathology and Pathological Physiology

Model of experimental depressive syndrome in rats induced by repeated systemic injection of proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine showed that chronic injection of prolylendopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine 30 min before pro-neurotoxin injection prevents the development of a number of depressive syndrome symptoms such as behavioral despair and biorhythmic disorders in forced swimming test, precludes the increase in anxiety-phobic level, prevents reduction of relative thymus mass. These results indicate that benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine possesses antidepressant, anxiolytic, and/antistress properties.

Key Words

experimental depressive syndrome 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine prolylendopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine rats 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    T. A. Voronina and S. B. Seredenin, Eksper. Klin. Farmakol., 65, No. 5, 4–17 (2002).Google Scholar
  2. 2.
    N. N. Zolotov, V. B. Narkevich, A. V. Prikhozhan, et al., Dokl. AN, 322, No. 4, 624–626 (1992).Google Scholar
  3. 3.
    N. A. Krupina, N. N. Zolotov, N. G. Bogdanov, et al., Bull. Eksper. Biol. Med., 142, No. 11, 497–499 (2006).Google Scholar
  4. 4.
    N. A. Krupina and G. N. Kryzhanovskiy, Zh. Nevrol. Psikhiatr. No. 4, 42–47 (2003).Google Scholar
  5. 5.
    G. N. Kryzhanovskii, N. A. Krupina, and V. G. Kucheryanu, Zh. Vyssh. Nervn. Deyat., 45, No. 2, 377–387 (1995).Google Scholar
  6. 6.
    V. B. Narkevichm, G. A. Nazarova, N. N. Zolotov, et al., Dokl. AN, 339, No. 5, 691–693 (1994).Google Scholar
  7. 7.
    V. I. Rodina, N. A. Krupina, G. N. Kryzhanovskii, and N. B. Oknina, Byull. Eksp. Biol. Med, 114, No. 7, 11–14 (1992).Google Scholar
  8. 8.
    C. Belzung, L. Yalcin, G. Griebel, et al., CNS Neurol Disord Drug Targets, 5, No. 2, 135–145 (2006).PubMedCrossRefGoogle Scholar
  9. 9.
    A. S. Elhwuegi, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, No. 3, 435–451 (2004).PubMedCrossRefGoogle Scholar
  10. 10.
    A. Holmes, M. Heiling, N.M. Rupniak, et al., Trends. Pharmacol. Sci., 24, No. 11, 580–588 (2003).PubMedCrossRefGoogle Scholar
  11. 11.
    M. Maes, F. Goossens, S. Scharpe, et al., Biol. Psychiatry, 35, No. 8, 545–552 (1994).PubMedCrossRefGoogle Scholar
  12. 12.
    M. Maes, S. Bonaccorso, V. Marino, et al., Mol. Psychiatry, 6, No. 4, 475–480 (2001).PubMedCrossRefGoogle Scholar
  13. 13.
    S. O. Reber, L. Birkeneder, A. H. Veenema, et al., Endocrinology, 148, No. 2, 670–682 (2006).PubMedCrossRefGoogle Scholar
  14. 14.
    J. S. Schneider, M. Giardiniere, and P. Morain, Neuropsychopharmacology, 26, No. 2, 176–182 (2002).PubMedCrossRefGoogle Scholar
  15. 15.
    Y. M. Ulrich-Lai, H. F. Figueiredo, M. M. Ostrander, et al., Am. J. Physiol. Endocrinol. Metab., 291, No. 5, E965–E973 (2006).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  • N. N. Khlebnikova
    • 1
  • N. A. Krupina
    • 1
  • N. G. Bogdanova
    • 1
  • N. N. Zolotov
    • 1
  • G. N. Kryzhanovskii
    • 1
  1. 1.Laboratory of General Pathology and Pathophysiology of Nervous System, Institute of General Pathology and PathophysiologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations